Debra Brandt, DO
Hematology & Oncology · Torrington, CTNPI 1710918032
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,645 of the $14,925 with a category attached, or 78.0%. AstraZeneca accounts for 61.2% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2024 at $5,385 and has fallen 65.2% since, to $1,875 in 2025.
Across 117 payments — averaging $127.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Immunocore Limited$2K
- Daiichi Sankyo Inc.$1K
- Athenex Pharmaceutical Division, LLC$500
- Tempus AI, Inc$306
- AbbVie$250
- plus $2K from 24 others
Across 2 payments — averaging $31,075 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$32K
- AbbVie$31K
What the payments were for
- Consulting fees$11,64578%
- Speaking & faculty fees$5003%
- Food & beverage$2,62518%
- Education$1551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $9,140 |
| Immunocore Limited | 2 | $2,023 |
| Daiichi Sankyo Inc. | 9 | $1,067 |
| Athenex Pharmaceutical Division, LLC | 1 | $500 |
| Tempus AI, Inc | 9 | $306 |
| AbbVie | 5 | $250 |
| Pfizer | 11 | $179 |
| Johnson & Johnson | 3 | $146 |
| Lilly USA, LLC | 5 | $138 |
| GSK | 6 | $135 |
| Bristol Myers Squibb | 5 | $128 |
| Sanofi | 3 | $122 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Amgen | 4 | $81 |
| Novartis | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Merck | 4 | $69 |
| Gilead | 4 | $59 |
| Genentech USA, Inc. | 2 | $57 |
| Astellas Pharma US Inc | 3 | $56 |
| Puma Biotechnology, Inc. | 2 | $52 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Bayer | 1 | $26 |
| Immunogen, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
| Seagen Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KIMMTRAK$2,000
- Enhertu$825
- Oral Paclitaxel$500
- Encequidar$500
- Elahere$135
How this compares
$14,925 in reported general payments places this provider in the 80th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 21 | $358,866 |
| VerzenioAbemaciclib | 13 | $197,809 |
| KisqaliRibociclib Succinate | 13 | $187,400 |
| EliquisApixaban | 13 | $8,166 |
| Anastrozole | 217 | $4,962 |
| Exemestane | 39 | $3,611 |
| Letrozole | 149 | $3,368 |
| Tamoxifen Citrate | 73 | $989 |
| Prochlorperazine Maleate | 54 | $587 |
| Oxycodone Hcl | 25 | $579 |
| Duloxetine Hcl | 14 | $532 |
| Dexamethasone | 39 | $469 |
| Trazodone Hcl | 19 | $364 |
| Famotidine | 51 | $305 |
| Olanzapine | 24 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $179 | $367,03234 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $138 | $198,09637 claims |
| NovartisKisqali | $72 | $187,40013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Torrington
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
- Walid ShaibNew Haven$217K
- Madhavi GorusuHartford$207K
- Dinesh KapurNorwich$201K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Justine RyuOrange$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.